(HealthDay)—Blood type is not associated with COVID-19 susceptibility or outcomes, according to a research letter published online April 5 in JAMA Network Open.
Jeffrey L. Anderson, M.D., from Intermountain Medical Center Heart Institute in Salt Lake City, and colleagues assessed whether blood type is associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility and COVID-19 severity. The analysis included 107,796 individuals who were tested for SARS-CoV-2 between March 3 and Nov. 2, 2020, at an integrated health care system of 24 hospitals and 215 clinics in Utah, Idaho, and Nevada.
The researchers found that blood type was not associated with disease susceptibility or severity, including viral positivity, hospitalization, or intensive care unit (ICU) admission. Type A was not associated with increased viral positivity (odds ratio, 0.97; 95 percent confidence interval, 0.93 to 1.01; P = 0.11), hospitalization (odds ratio, 0.89; 95 percent confidence interval, 0.80 to 0.99; P = 0.03), or ICU admission (odds ratio, 0.84; 95 percent confidence interval, 0.69 to 1.02; P = 0.08) compared with type O blood. Outcomes were no worse for types B or AB than for type O. Results were similar for analyses restricted to White patients.
“Given the large and prospective nature of our study and its strongly null results, we believe that important associations of SARS-CoV-2 and COVID-19 with ABO groups are unlikely and will not be useful factors associated with disease susceptibility or severity on either an individual or population level for similar environments and ancestries,” the authors write.
One author disclosed financial ties to AstraZeneca and GlaxoSmithKline.
Follow the latest news on the coronavirus (COVID-19) outbreak
Copyright © 2021 HealthDay. All rights reserved.
Blood type not associated with COVID-19 outcomes (2021, April 9)
retrieved 10 April 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022